Drug Trial Radar · NCT06642545
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Last checked: Nov 19, 2026Latest source record: Feb 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Feb 10, 2025
Primary completion
Oct 1, 2026
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluating the Efficacy of Disitamab Vedotin in Combination with RC148 Compared to Albumin-bound Paclitaxone Monotherapy or in Combination with Toripalimab for Subjects with HR-negative, HER2-low Expressing Unresectable Locally Advanced or Metastatic Breast Cancer
Conditions
- Breast Cancer
Interventions
Disitamab VedotinDrug
Disitamab Vedotin 2.0mg/kg,intravenous infusion, every 2 weeks
RC148Drug
20mg/kg, intravenous infusion, once every 2 weeks
Albumin-bound PaclitaxoneDrug
125 mg/m2,intravenous infusion, D1-8, every 3 weeks
ToripalimabDrug
240mg,intravenous infusion, once every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cance Hosoltal Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.